Finnrick, an independent testing programme, publishes 76 assays for Xingruida XDR: 53 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 23 did not. Most recent assay 3 Aug 2026.
Xingruida XDR operates from China, listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/xingruida-xdr.
Finnrick-tested with mixed results. Tested across 6 peptide products with 65 total samples.
Xingruida XDR is listed as active. Finnrick Grade C. Finnrick avg score: 7.4/10 across 65 samples (6 products). Mixed quality — some products test well, others below average.
Xingruida XDR holds independent lab grade C, assigned across 65 graded samples, average score 7.4/10. That grade comes from an independent grader's own sampling, not from PeptideAtlas, and it describes the samples that grader obtained rather than every batch sold.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 27 | 22 passed, 5 failed |
| Tirzepatide | 22 | 17 passed, 5 failed |
| GHK-Cu | 9 | 4 passed, 5 failed |
| BPC-157 | 8 | 5 passed, 3 failed |
| Tesamorelin | 8 | 4 passed, 4 failed |
| Melanotan II | 2 | 1 passed, 1 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Independent lab grade | C (65 samples) |
| Average grader score | 7.4/10 |
| Vendor type | Research-use supplier |
| Satisfaction | 0.3/5 |
|---|---|
| Delivery | 3.6/5 |
| Customer service | 2.3/5 |
| Packaging | 4/5 |
| Ease of purchase | 2.9/5 |
| Payment | 4.1/5 |
Scored out of 5 by the same independent grader, from its own buyers rather than from this site.
These details were read from Xingruida XDR's own website on 2026-08-17. Pages consulted:
Xingruida XDR is listed as active and we hold 76 Finnrick assays (53 passing, 23 failing its purity threshold); an independent lab grade of C. That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 76 assays for Xingruida XDR: 53 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 23 did not. Most recent assay 3 Aug 2026.
Similar vendors: Peptide Sciences, Limitless Life Nootropics, Polaris Peptides, NextechLabs, Yiwu Aozuo Trading Co, Shandong Shengyuan Peptide Technology, Bulk Peptide Supply, Skye Peptides.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Xingtai Jiachuang Technology Peptides Review, Xingtai Lesda Technology Peptides Review, Xingtai Pukelai Technology Co Peptides Review.